Pazopanib
CAS 444731-52-6 4 FDA-DMF suppliersSmall Molecule
Overview
Pazopanib is a potent multi-targeted receptor tyrosine kinase inhibitor that inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α/β, and c-Kit. It is used in the treatment of renal cell carcinoma and soft tissue sarcoma.
Patent & exclusivity (US)
Per the FDA Orange Book (7 approved US products), the latest listed US patent on Pazopanib expires — and exclusivity 5 May 2026. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologyNephrology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.